Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 5/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29423910 | 1.00 | FFAR1 (0.38) | FFAR1ROCK1SCN3AHIF1ABACE1 | |
| SCHEMBL29423898 | 1.00 | FFAR1 (0.38) | FFAR1ROCK1SCN3AHIF1ABACE1 | |
| SCHEMBL19669155 | 0.90 | ROCK1 (0.38) | FFAR1ROCK1SCN3AHIF1ABACE1 | |
| SCHEMBL18940276 | 0.90 | FFAR1 (0.43) | FFAR1ROCK1SCN3AHIF1ABACE1 | |
| SCHEMBL18940306 | 0.90 | FFAR1 (0.43) | FFAR1ROCK1SCN3AHIF1ABACE1 | |
| SCHEMBL23927778 | 0.90 | FFAR1 (0.43) | FFAR1ROCK1SCN3AHIF1ABACE1 | |
| SCHEMBL15465576 | 0.88 | FFAR1 (0.49) | FFAR1ROCK1HIF1ABACE1BACE2 | |
| SCHEMBL15471368 | 0.88 | FFAR1 (0.49) | FFAR1ROCK1HIF1ABACE1BACE2 | |
| SCHEMBL29423893 | 0.86 | FFAR1 (0.41) | FFAR1 | |
| SCHEMBL16846002 | 0.86 | FFAR1 (0.41) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834563-B2 | Antidiabetic substituted heteroaryl compounds | MERCK SHARP & DOHME CORP. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834563-B2 | Antidiabetic substituted heteroaryl compounds | MERCK SHARP & DOHME CORP. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170166578-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-06-15 | — | — | US | disclosed |
| US-20170166578-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-06-15 | — | — | US | disclosed |
| WO-2015095256-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015089809-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166578-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | GPR119, GPR65, GPR55 | FFAR1 13/4885ROCK1 3440/4885SCN3A 2870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.